

Second-Quarter Fiscal 2019 Earnings

April 30, 2019



ashland.com / efficacy usability allure integrity profitability



AshlandTM
always solving

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the SEC, news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance and financial condition, as well as the economy and other future events or circumstances. These statements include, but may not be limited to, the statements under “Fiscal Year 2019 Outlook” on page 9 of the presentation, “Cost Reduction Targets” on page 10 of the presentation, “Third-Quarter Fiscal 2019 Outlook” on page 11 of the presentation, Ashland's assessment on its progress towards becoming a premier specialty chemicals company and its expectations regarding its ability to drive sales and earnings growth, realize future cost reductions and complete the anticipated divestiture of its Composites business and Marl BDO facility. Ashland's expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the program to eliminate certain existing corporate and Specialty Ingredients expenses (including the possibility that such cost eliminations may not occur or may take longer to implement than anticipated), the expected divestiture of its Composites segment and the Marl BDO facility, and related merchant I&S products (including, in each case, the possibility that a transaction may not occur or that, if a transaction does occur, Ashland may not realize the anticipated benefits from such transaction), the impact of acquisitions and/or divestitures Ashland has made or may make (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland's substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland's future cash flows, results of operations, financial condition and its ability to repay debt); Ashland's ability to generate sufficient cash to finance its stock repurchase plans; severe weather, natural disasters, cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters); and without limitation, risks and uncertainties affecting Ashland that are described in Ashland's most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at <http://investor.ashland.com> or on the SEC's website at <http://www.sec.gov>. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.

Regulation G: Adjusted Results

The information presented herein regarding certain unaudited adjusted results does not conform to generally accepted accounting principles in the United States (U.S. GAAP) and should not be construed as an alternative to the reported results determined in accordance with U.S. GAAP. Ashland has included this non-GAAP information to assist in understanding the operating performance of the company and its reportable segments. The non-GAAP information provided may not be consistent with the methodologies used by other companies. All non-GAAP information has been reconciled with reported U.S. GAAP results. Although Ashland provides forward-looking guidance for adjusted EBITDA, free cash flow and adjusted diluted earnings per share, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP-reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure. Such reconciliations have not been included because Ashland is unable, without unreasonable efforts, to estimate and quantify the most directly comparable U.S. GAAP components, largely because predicting future operating results is subject to many factors not in Ashland's control and not readily predictable and that are not part of Ashland's routine operating activities, including various domestic and international economic, political, legislative, regulatory and legal factors.



Second Quarter Summary

Adjusted Results Summary¹

(\$ in millions) Preliminary	Fiscal Second Quarter Three months ended Mar. 31,		
	2019	2018	Change
Sales	\$ 667	\$ 672	(1) %
Gross profit	\$ 217	\$ 224	(3) %
Gross profit as a percent of sales	32.5 %	33.3 %	(80) bp
Selling, general and admin./R&D costs	\$ 136	\$ 154	(12) %
Operating income	\$ 81	\$ 70	16 %
Operating income as a percent of sales	12.1 %	10.4 %	170 bp
Depreciation and amortization	\$ 62	\$ 67	(7) %
Earnings before interest, taxes, depreciation and amortization (EBITDA)	\$ 142	\$ 138	3 %
EBITDA as a percent of sales	21.3 %	20.5 %	80 bp
Net interest expense	\$ 24	\$ 24	- %
Effective tax rate	6 %	10 %	(400) bp
Income from continuing operations	\$ 52	\$ 43	21 %
Diluted share count (million shares)	64	64	- %
Earnings per share (EPS)	\$ 0.83	\$ 0.67	24 %

Highlights & Key Drivers

- Reflects discontinued operations accounting for Composites and Marl butanediol (BDO) facility; continuing operations includes Specialty Ingredients and Lima BDO facility
- Sales down 1% including a -3 percentage point (ppt) impact from foreign currency and a -1 ppt impact from the Colgate-Gantrez oral-care reformulation²
- Gross profit negatively impacted by foreign currency and unfavorable product mix within Specialty Ingredients
- Selling, general & administrative (SG&A) expense reduced by \$18 million due primarily to the ongoing cost reduction program and inclusive of \$3 million of favorable currency
- Reported net income of \$76 million, compared to income of \$73 million last year; income from continuing operations was \$45 million or \$0.71 per diluted share³
- EBITDA increased to \$142 million vs. \$138 million prior year inclusive of a negative \$6 million foreign-currency impact
- Effective tax rate of 6% driven by income mix and favorable discrete items
- EPS increased to \$0.83 vs. \$0.67 prior year
- Excluding intangible amortization, EPS would have been \$0.25 greater

¹ All figures are presented on an adjusted basis except Sales, Diluted share count (million shares) and net income. Appendix C reconciles adjusted amounts to amounts reported under GAAP, including reconciliations of net income to EBITDA and adjusted EBITDA, operating income to adjusted operating income, income (loss) from continuing operations to adjusted income from continuing operations and diluted earnings per share to adjusted diluted earnings per share.

² As disclosed on the fiscal-fourth quarter 2018 earnings call.

³ Unless otherwise noted, earnings are reported on a diluted share basis.

Specialty Ingredients Adjusted Results Summary¹

(\$ in millions) Preliminary	Fiscal Second Quarter		
	Three months ended Mar. 31,		
	2019	2018	Change
Sales	\$ 637	\$ 646	(1) %
Gross profit	\$ 210	\$ 218	(4) %
Gross profit as a percent of sales	33.0 %	33.6 %	(60) bp
Selling, general and admin./R&D costs	\$ 119	\$ 127	(6) %
Operating income	\$ 90	\$ 91	(1) %
Operating income as a percent of sales	14.1 %	14.1 %	- bp
Depreciation and amortization	\$ 58	\$ 62	(6) %
Earnings before interest, taxes, depreciation and amortization (EBITDA)	\$ 148	\$ 153	(3) %
EBITDA as a percent of sales	23.2 %	23.7 %	(50) bp

Highlights & Key Drivers

- Sales down 1% including a -3 ppt impact from currency and -1 ppt impact from the Colgate oral-care reformulation²
- Continued pricing above raw-material inflation
- Gross profit negatively impacted by foreign currency and product mix
- SG&A down \$8 million and nearly 100 bps as % of sales due primarily to the ongoing cost reduction program
- EBITDA declined to \$148 million; foreign currency negatively impacted EBITDA growth by 4% or \$6 million

¹ All figures are presented on an adjusted basis except Sales and Selling, general and admin./R&D costs. Appendix C reconciles adjusted amounts to amounts reported under GAAP, including reconciliations of operating income to adjusted EBITDA and operating income to adjusted operating income.

² As disclosed on the fiscal-fourth quarter 2018 earnings call.

Specialty Ingredients

Sales Trends by End Market

(\$ in millions) Preliminary	Fiscal Second Quarter		
	Three months ended Mar. 31,		
	2019	2018	Change
Personal care	\$154	\$154	- %
Pharma	106	104	2 %
Adhesives	89	89	- %
Coatings	85	84	1 %
Construction, Energy, PS ¹	84	81	4 %
Nutrition & Other	55	53	4 %
Pharmachem	64	63	2 %
Constant-FX subtotal	\$637	\$628	2 %
Impact of foreign exchange ²	-	18	NM %
Sales (as reported)	\$637	\$646	(1) %

End Market Commentary

- Sales grew 3% excluding the impact of foreign currency (-3 ppts²) and Colgate-Gantrez (-1 ppt)
- Personal Care constant-currency sales grew 5%, excluding the impact of Colgate-Gantrez, driven by innovations and new business wins with skin- and hair-care customers
- Pharma growth led by cellulosic-exciptent technologies; results in the context of strong prior-year results with increased excipient capacity at Hopewell and Doel
- Gains in Adhesives pricing partially offset weak demand
- Successful effort to grow Coatings share in emerging regions partially offset by weak demand in North America and Europe
- To offset weakness in other end markets, focused growth in lower-margin Construction, Energy and Nutrition
- Pharmachem growth reflects expanded customer relationships

1 Performance Specialties

2 Average USD / EUR of \$1.13 in current quarter compared to \$1.23 in prior-year period. 2018 results restated to 2019 foreign exchange rates.

Intermediates & Solvents

Adjusted Results Summary¹

(\$ in millions) Preliminary	Fiscal Second Quarter		
	Three months ended Mar. 31,		
	2019	2018	Change
Sales	\$ 30	\$ 26	15 %
Gross profit	\$ 8	\$ 6	33 %
Gross profit as a percent of sales	26.1 %	22.8 %	330 bp
Selling, general and admin./R&D costs	\$ 3	\$ 3	- %
Operating income	\$ 5	\$ 3	67 %
Operating income as a percent of sales	16.7 %	11.5 %	520 bp
Depreciation and amortization	\$ 3	\$ 3	- %
Earnings before interest, taxes, depreciation and amortization (EBITDA)	\$ 8	\$ 6	33 %
EBITDA as a percent of sales	26.7 %	23.1 %	360 bp

Highlights & Key Drivers

- Reflects results of the Lima, Ohio facility only; Marl facility reported in discontinued operations
- Sales, gross profit and EBITDA increased due to higher volumes and improved pricing compared to prior year
- Sales up 15% to \$30 million
- EBITDA increased to \$8 million
- EBITDA margin increased to 26.7%

¹ All figures are presented on an unadjusted basis.

Outlook Summary



Ashland Global Holdings Inc.

Fiscal Year 2019 Outlook

Key Drivers

- Adjusted EPS and Specialty Ingredients' Adjusted EBITDA outlook reduced primarily due to:
 - Lower-than-expected Q2 results due to weaker demand in higher-margin end markets offset by focused selling in Construction, Energy and Nutrition
 - Inclusive of \$19 million full-year negative foreign currency impact, \$7 million worse than original expectations
- Actions are being taken to offset new expectations and the potential for continued low growth in Coatings and Adhesives demand during the second half of the fiscal year. Midpoint of Updated Outlook implies:
 - Demand recovery by Q4 of fiscal 2019
 - ~4% Specialty Ingredients Adjusted EBITDA year-over-year growth, including ~\$20 million SG&A reduction and the negative foreign-currency impact
- Expect to return to normalized sales growth and high single-digit EBITDA growth by the beginning of fiscal year 2020
 - Lap the impact of currency and the Colgate-Gantrez reformulation by the end of fiscal Q4
 - Return to normal demand environment later in the calendar year
 - Realize ~\$30 million benefit within Specialty Ingredients from the current cost reduction program
- Free cash flow¹ outlook inclusive of an estimated \$40 million of separation and restructuring-related costs
- Intend to initiate a \$200 million share repurchase program to begin in early May


	Prior Outlook	Updated Outlook
Adjusted EBITDA		
- Specialty Ingredients	\$610 - \$635 million	\$585 - \$610 million
- Intermediates & Solvents	\$20 - \$30 million	Reaffirmed
- Unallocated and Other	(\$50 - \$60 million)	(\$45 - \$55 million)
Key Operating Metrics		
- Adj. earnings per share (EPS)	\$3.10 - \$3.40	\$2.90 - \$3.20
- Free cash flow ¹	~\$175 million	\$165 - \$175 million
Corporate Items		
- Depreciation & amortization	~\$260 million	~\$250 million
- Interest expense	\$85 - \$95 million	\$90 - \$100 million
- Effective tax rate	14 - 16%	Reaffirmed
- Capital expenditures	~\$160 million	Reaffirmed
- Diluted share count	~64 million	~63 million

Ashland Global Holdings Inc.

Cost Reduction Targets

As presented on July 31, 2018

\$120 million cost savings components¹



Expected Timing

- ~\$20 million run rate² as of 9/30/18
- ~\$50 million run rate² as of 12/31/18
- ~\$60 - \$70 million realized savings in FY2019
- ~\$20 million realized savings in Specialty Ingredients in FY2019
- ~\$120 million run rate² by 12/31/19

\$50 million Specialty Ingredients reduction

\$70 million of transferred / stranded costs

Achieved \$70 million run-rate as of March 31st;
Remain on track to achieve all cost reduction program targets

Third-Quarter Fiscal 2019 Outlook

Highlights

- Expect Q3 adjusted EPS¹ in the range of \$0.80 - \$0.90
- Outlook assumes effective tax rate of 15 percent
- Outlook reflects discontinued operations accounting for Composites and the Marl BDO facility

Key Drivers

- Low single-digit increase in Specialty Ingredients' year-over-year Adjusted EBITDA
 - Growth in the context of weaker Coatings and Adhesives demand, targeted sales efforts, unfavorable foreign currency² and the Colgate-Gantrez oral-care reformulation
- On track to achieve all cost reduction program targets
- The divestiture of Composites and the Marl BDO facility remains on track; we are awaiting regulatory approval and expect a closing by late summer
- Intend to initiate a \$200 million share repurchase program to begin in early May

1 Non-GAAP measure. Appendix C reconciles reported adjusted amounts to amounts reported under GAAP, including reconciliations of diluted earnings per share to adjusted diluted earnings per share. Forecasted information is not reconciled to applicable US GAAP captions.

2. Estimated currency sensitivity, primarily driven by the Euro, of approximately \$1.5 million of annual adjusted EBITDA per year-over-year Euro cent change.

Appendix A: Key Items and Balance Sheet

Second Fiscal Quarter – Continuing Operations

Key Items Affecting Income

(\$ in millions, except EPS) Preliminary				Total		
2019	Specialty Ingredients	I&S	Unallocated and Other	Pre-tax	After-tax	After-tax earnings per Share
Restructuring, separation and other costs	\$ (20)		\$ (12)	\$ (32)	\$ (29)	\$ (0.46)
Proxy costs			(5)	\$ (5)	(4)	(0.06)
Unrealized gain on securities			27	\$ 27	21	0.32
Tax specific key items				\$ -	5	0.08
Total	\$ (20)		\$ 10	\$ (10)	\$ (7)	\$ (0.12)
2018						
Restructuring, separation and other costs	\$ (2)		\$ (10)	\$ (12)	\$ (9)	\$ (0.14)
Legal settlement			5	5	4	0.05
Tax specific key items				-	4	0.07
Total	\$ (2)	\$ -	\$ (5)	\$ (7)	\$ (1)	\$ (0.02)

Liquidity and Net Debt

(\$ in millions)

Liquidity	
Cash	\$ 164
Revolver and A/R facility availability	741
Liquidity	\$ 905

Debt	Expiration	Interest			
		Rate	Moody's	S&P	
4.750% senior notes, par \$1,086	08/2022	4.750%	Ba3	BB-	\$ 1,083
Term Loan B ¹	05/2024	L+175	Ba1	BB+	590
6.875% senior notes, par \$375	05/2043	6.875%	Ba3	BB-	376
Term Loan A-2 ²	05/2022	L+175	Ba1	BB+	195
European A/R facility drawn ³	07/2020	CP+70			106
U.S. A/R facility drawn ⁴	03/2020	L+75/CP+60			101
6.5% debentures, par \$100	06/2029	6.500%	B2	BB	53
Revolver drawn ⁵	05/2022	L + 175	Ba1	BB+	25
Other debt ⁶					7
Total debt			Ba2 / Stable	BB / Stable	\$ 2,536
Cash					\$ 164
Net debt (cash)					\$ 2,372

¹ The Term Loan B has an amortizing principal, with complete repayment in 2024.

² The Term Loan A-2 has an amortizing principal, with complete repayment in 2022.

³ Ashland has a multi-currency European AR securitization facility with maximum borrowing capacity of €115 million; March 31 capacity of €0 million.

⁴ Ashland has a U.S. AR securitization facility with maximum borrowing capacity of \$115 million; March 31 capacity of \$14 million.

⁵ Ashland's \$800 million revolving facility, including \$48 million used for letters of credit; March 31 capacity of \$727 million.

⁶ Includes \$19 million of debt-issuance cost discounts.



Appendix B: Business Profiles


12 Months Ended March 31, 2019




Specialty Ingredients

A global leader of cellulose ethers, vinyl pyrrolidones and biofunctionals


Sales by Market¹



Sales by Product



Sales by Geography



For 12 Months Ended March 31, 2019

Sales: \$2.5 billion

Adjusted EBITDA: \$575 million

Adjusted EBITDA Margin: 23.3%

¹ Within the Sales by Market chart above, Industrial Specialties are presented in green and Consumer Specialties are presented in blue.

Appendix C: Non-GAAP Reconciliation¹

- ¹ Although Ashland provides forward looking guidance for adjusted EBITDA in this presentation, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort.



Ashland Global Holdings Inc. and Consolidated Subsidiaries
Reconciliation of Non-GAAP Data
 for 6 Months Ended March 31, 2019

(\$ millions, except percentages)

Sales ¹	Q2 19	Q1 19	Total	
Specialty Ingredients	637	553	1,190	
Intermediates and Solvents	30	23	53	
Total	667	576	1,243	
				Adjusted EBITDA Margin
Adjusted EBITDA ¹	Q2 19	Q1 19	Total	
Specialty Ingredients	148	112	260	21.8%
Intermediates and Solvents	8	3	11	20.8%
Unallocated	(14)	(15)	(29)	
Total	142	100	242	

¹ Quarterly totals may not sum to actual results due to quarterly rounding conventions. Calculation of adjusted EBITDA for each quarter has been reconciled within certain financial filings with the SEC and posted on Ashland's website for each reportable segment.

Ashland Global Holdings Inc. and Consolidated Subsidiaries
**Segment Components of Key Items for Applicable
Income Statement Captions**
for 3 Months Ended March 31, 2019

(\$ millions)

	<u>Specialty Ingredients</u>	<u>Intermediates and Solvents</u>	<u>Unallocated & Other</u>	<u>Total</u>
OPERATING INCOME (LOSS)				
Operating key items:				
Restructuring, separation and other costs	\$ (20)	\$ -	\$ (12)	\$ (32)
Proxy costs	-	-	(5)	(5)
All other operating income (loss)	<u>90</u>	<u>5</u>	<u>(14)</u>	<u>81</u>
Operating income (loss)	70	5	(31)	44
NET INTEREST AND OTHER EXPENSE (INCOME)				
Key items			(27)	(27)
All other net interest and other expense (income)			24	24
OTHER NET PERIODIC BENEFIT INCOME				
All other net periodic benefit income			(1)	(1)
INCOME TAX EXPENSE (BENEFIT)				
Tax effect of key items ¹			2	2
Tax specific key items ²			(5)	(5)
All other income tax expense			<u>4</u>	<u>4</u>
			<u>1</u>	<u>1</u>
INCOME (LOSS) FROM CONTINUING OPERATIONS	<u>\$ 70</u>	<u>\$ 5</u>	<u>\$ (30)</u>	<u>\$ 45</u>

¹ Represents the tax effect of the key items that are previously identified above.

² Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items.

Ashland Global Holdings Inc. and Consolidated Subsidiaries

Segment Components of Key Items for Applicable Income Statement Captions

for 3 Months Ended March 31, 2018

(\$ millions)

	<u>Specialty Ingredients</u>	<u>Intermediates and Solvents</u>	<u>Unallocated & Other</u>	<u>Total</u>
OPERATING INCOME (LOSS)				
Operating key items:				
Restructuring, separation and other costs	\$ (2)	\$ -	\$ (10)	\$ (12)
Legal settlement	-	-	5	5
All other operating income (loss)	<u>91</u>	<u>3</u>	<u>(24)</u>	<u>70</u>
Operating income (loss)	89	3	(29)	63
NET INTEREST AND OTHER EXPENSE (INCOME)			24	24
OTHR NET PERIODIC BENEFIT INCOME (EXPENSE)			1	1
INCOME TAX EXPENSE (BENEFIT)				
Tax effect of key items ¹			(2)	(2)
Tax specific key items ²			(4)	(4)
All other income tax expense			<u>4</u>	<u>4</u>
INCOME (LOSS) FROM CONTINUING OPERATIONS	<u>\$ 89</u>	<u>\$ 3</u>	<u>\$ (50)</u>	<u>\$ 42</u>

¹ Represents the tax effect of the key items that are previously identified above.

² Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items.

Ashland Global Holdings Inc. and Consolidated Subsidiaries

Reconciliation of Non-GAAP Data – Free Cash Flow and Adjusted Operating Income

for 3 Months Ended March 31, 2019 and 2018

(\$ millions)

	Three months ended March 31	
	2019	2018
Free cash flows¹		
Total cash flows used by operating activities from continuing operations	\$ 15	\$ 28
Adjustments:		
Additions to property, plant and equipment	(37)	(31)
Free cash flows ¹	<u>\$ (22)</u>	<u>\$ (3)</u>

	Three months ended March 31	
	2019	2018
Adjusted operating income (loss)		
Operating income (loss) (as reported)	\$ 44	\$ 63
Key items, before tax:		
Restructuring, separation and other costs	32	12
Proxy costs	5	-
Legal settlement/reserve	-	(5)
Adjusted operating income (non-GAAP)	<u>\$ 81</u>	<u>\$ 70</u>

¹ Free cash flow is defined as cash flows provided (used) by operating activities less additions to property, plant and equipment and other items Ashland has deemed non-operational (if applicable).

Ashland Global Holdings Inc.

Reconciliation of Non-GAAP Data – Adjusted EBITDA for 3 Months Ended March 31, 2019 and 2018

(\$ millions)

	Three months ended March 31	
	2019	2018
Adjusted EBITDA - Ashland Global Holdings Inc.		
Net loss	\$ 76	\$ 73
Income tax expense	1	(2)
Net interest and other expense (income)	(3)	24
Depreciation and amortization ¹	62	67
EBITDA	136	162
Income from discontinued operations (net of taxes)	(31)	(31)
Operating key items	37	7
Adjusted EBITDA	\$ 142	\$ 138

¹ Depreciation and amortization excludes accelerated depreciation of \$19 million and \$2 million for Specialty Ingredients for the three months ended March 31, 2019 and 2018, respectively, and \$1 million and \$3 million for Unallocated and other for the three months ended March 31, 2019 and 2018, respectively, which are

22 included as key items within this table.



Specialty Ingredients, Intermediates and Solvents

Reconciliation of Non-GAAP Data – Adjusted EBITDA

for 3 Months Ended March 31, 2019 and 2018

(\$ millions)

	Three months ended March 31	
	2019	2018
<u>Adjusted EBITDA - Specialty Ingredients</u>		
Operating income	\$ 70	\$ 89
Add:		
Depreciation and amortization ¹	58	62
Operating key items	20	2
Adjusted EBITDA	<u>\$ 148</u>	<u>\$ 153</u>
 <u>Adjusted EBITDA - Intermediates and Solvents</u>		
Operating income	\$ 5	\$ 3
Add:		
Depreciation and amortization	3	3
Operating key items	-	-
Adjusted EBITDA	<u>\$ 8</u>	<u>\$ 6</u>

¹ Depreciation and amortization excludes accelerated depreciation of \$19 million and \$2 million for Specialty Ingredients for the three months ended March 31, 2019 and 2018, respectively, and \$1 million and \$3 million for Unallocated and other for the three months ended March 31, 2019 and 2018, respectively, which are included as key items within this table.

Ashland Global Holdings Inc. and Consolidated Subsidiaries

Reconciliation of Non-GAAP Data – Adjusted Income from Continuing Operations

for 3 Months Ended March 31, 2019 and 2018

(\$ millions)

	Three months ended March 31	
	2019	2018
Income (loss) from continuing operations (as reported)	\$ 45	\$ 42
Key items, before tax:		
Restructuring, separation and other costs	32	12
Proxy costs	5	-
Legal settlement	-	(5)
Unrealized (gain) loss on securities	(27)	-
Key items, before tax	10	7
Tax effect of key items ¹	2	(2)
Key items, after tax	12	5
Tax specific key items:		
Deferred tax rate changes	-	(4)
Restructuring and separation activity	(2)	-
Other tax reform	(3)	-
Tax specific key items ²	(5)	(4)
Total key items	7	1
Adjusted income from continuing operations (non-GAAP)	\$ 52	\$ 43

¹ Represents the tax effect of the key items that are previously identified above.

² Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

- Deferred tax rate changes: Includes the impact from the remeasurement of Ashland's domestic deferred tax balances resulting from the enactment of the Tax Cuts and Jobs Act (Tax Act) as well as the impact from rate changes for other jurisdictions.
- Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.
- Other tax reform: Includes the impact of other items related to the Tax Act and other tax law. These adjustments include the impact from the deductibility of compensation items and miscellaneous state tax items.

Ashland Global Holdings Inc. and Consolidated Subsidiaries

Reconciliation of Non-GAAP Data – Adjusted Diluted EPS from Continuing Operations


for 3 Months Ended March 31, 2019 and 2018

	Three months ended March 31	
	2019	2018
Diluted EPS from continuing operations (as reported)	\$ 0.71	\$ 0.65
Key items, before tax:		
Restructuring, separation and other costs	0.50	0.19
Proxy costs	0.08	-
Legal settlement	-	(0.07)
Unrealized (gain) loss on securities	(0.42)	-
Key items, before tax	0.16	0.12
Tax effect of key items ¹	0.04	(0.03)
Key items, after tax	0.20	0.09
Tax specific key items:		
Deferred tax rate changes	-	(0.07)
Restructuring and separation activity	(0.03)	-
Other tax reform	(0.05)	-
Tax specific key items ²	(0.08)	(0.07)
Total key items	0.12	0.02
Adjusted diluted EPS from continuing operations (non-GAAP)	\$ 0.83	\$ 0.67

¹ Represents the tax effect of the key items that are previously identified above.

² Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

- Deferred tax rate changes: Includes the impact from the remeasurement of Ashland's domestic deferred tax balances resulting from the enactment of the Tax Cuts and Jobs Act (Tax Act) as well as the impact from rate changes for other jurisdictions.
- Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.
- Other tax reform: Includes the impact of other items related to the Tax Act and other tax law. These adjustments include the impact from the deductibility of compensation items and miscellaneous state tax items.



AshlandTM
always solving